This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Harvard College. Active years: 2014.
Company Filing History:
Years Active: 2014
Title: Bo Chen - Innovator in Retinal Disease Treatment
Introduction
Bo Chen is a prominent inventor based in Cambridge, MA, specializing in innovative methods for treating retinal diseases. His work focuses on the administration of HDAC4 nucleic acids, which has the potential to significantly impact the field of ophthalmology.
Latest Patents
Bo Chen holds a patent for "HDAC4 nucleic acid administration to treat retinal disease." This patent outlines methods for inhibiting retinal cell death by altering the expression of one or more of HDAC4, HDAC5, HDAC6, HDAC7, and HIF1α in retinal cells. This groundbreaking approach aims to provide new avenues for treating retinal conditions that currently lack effective therapies.
Career Highlights
Bo Chen is affiliated with Harvard College, where he contributes to cutting-edge research in the field of retinal health. His dedication to advancing medical science is evident through his innovative patent and ongoing research efforts.
Collaborations
Bo Chen collaborates with Constance L. Cepko, a fellow researcher at Harvard College. Their partnership enhances the potential for breakthroughs in retinal disease treatment.
Conclusion
Bo Chen's contributions to the field of retinal disease treatment through his innovative patent demonstrate his commitment to improving patient outcomes. His work at Harvard College, alongside esteemed colleagues, positions him as a key figure in the advancement of ophthalmic research.